India In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO Synapse Labs. While the Indian government has taken steps to regulate the industry and improve quality, including a new Drugs,…
Global Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to ensure greater access to their essential products. Martinez argues that for people living in low-and middle-income countries (LMICs), generic and…
India A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory; the government’s revision of Good Manufacturing Practices (GMP) in light of deaths linked to Indian-made cough syrups; Torrent Pharma’s new…
Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…
Global With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not surprising that a number of generics producers continue to rank among the world’s top pharma companies. A look at the…
Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…
Global The Israeli giant began as a wholesale drug business more than a century ago and went on to dominate the global generics market until it lost its leadership position in 2021. After the setbacks of a costly acquisition and several reputational challenges, Teva is pushing to stay on track. Teva…
Spain Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to global chief commercial officer. Schüberg got his first pharma job at Lundbeck in 1994 after serving in the Swedish…
USA Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might evolve post-COVID. AAM and our member companies have experienced a year like no other, and the lessons of the…
Russia The latest Russia Pharma News, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce insulin in Venezuela, the bypassing of Gilead’s Remdesivir IP, and the Russian government’s decision to delay approvals of Chinese vaccines in favor of local shots. Russian Biocad plans to produce…
Russia The latest news from Russian pharma and healthcare including a big funding injection for primary care up to 2025, limits on pharma companies’ ability to patent other forms of already known chemical compounds in Russia, and the Sputnik COVID-19 vaccine’s geopolitical cachet. Russia to allocate $7.4 bln for healthcare…
Global The top ten global generics and biosimilars companies according to a recent Informa Pharma Intelligence ranking for 2019. Sandoz leads the way in terms of revenues from generics, biosimilars, APIs, and OTC drugs, followed by Mylan – which recently merged with Pfizer’s Upjohn unit to form a new company, ‘Viatris’…
See our Cookie Privacy Policy Here
